Fulvestrant Injection

Effects and efficacy:
Fulvestrant is mainly used for postmenopausal (including natural menopause and artificial menopause) women with locally advanced or metastatic breast cancer that relapses after or during anti-estrogen adjuvant therapy, or progresses during anti-estrogen therapy.
Usage and dosage:
For locally advanced or metastatic breast cancer, intramuscular injection in the buttocks, the recommended dose is 500 mg once, administered once a month, and another 500 mg dose is required two weeks after the first dose. Instructions for administration: Two 5 ml injections are injected slowly and continuously into the buttocks (each 5 ml injection takes about 1-2 minutes), one injection in each buttock. Due to the proximity to the sciatic nerve below, caution should be exercised when injecting this product in the upper outer quadrant of the buttocks muscle.
Drug contraindications:
Allergy to this product is prohibited. It is prohibited during pregnancy. It is prohibited during lactation. It is prohibited for children. It is used with caution by athletes. It is used with caution in liver and kidney dysfunction.
Related dosage forms:
Injection